source
- Pfizer partners with Sciwind to launch GLP-1 obesity drug Ecnoglutide in ChinaPfizer is entering China's obesity market with a new GLP-1 drug, Ecnoglutide, in partnership with Sciwind Biosciences. The New York-based company secured mainland China licensing rights to the inj…
- Live discussion to assess how US midterm elections could reshape biopharma policyDrew Armstrong, executive editor of PharmaFDA+, announced a live webcast at 1:30 pm ET on November 3, 2026 to discuss the impact of the US midterm elections on biotech and pharma. The program will…